Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Other Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $9000.0 as the latest value for Q1 2022.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $9000.0 in Q1 2022 year-over-year; TTM through Mar 2022 was $9000.0, a N/A change, with the full-year FY2021 number at $17000.0, down 90.34% from a year prior.
  • Other Non-Current Liabilities was $9000.0 for Q1 2022 at Caribou Biosciences, down from $17000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $176000.0 in Q4 2020 to a low of $9000.0 in Q1 2022.
  • A 3-year average of $103600.0 and a median of $153000.0 in 2021 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 90.34% in 2021; the steepest drop was 90.34% in 2021.
  • Caribou Biosciences' Other Non-Current Liabilities stood at $176000.0 in 2020, then crashed by 90.34% to $17000.0 in 2021, then plummeted by 47.06% to $9000.0 in 2022.
  • Per Business Quant, the three most recent readings for CRBU's Other Non-Current Liabilities are $9000.0 (Q1 2022), $17000.0 (Q4 2021), and $153000.0 (Q3 2021).